Inicio>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>MS049

MS049

Catalog No.GC36656

MS049 es un inhibidor dual potente, selectivo y celularmente activo de PRMT4 y PRMT6 con IC50 de 34 nM y 43 nM, respectivamente. MS049 reduce los niveles de Med12me2a y H3R2me2a en las células HEK293. MS049 no es tÓxico y no afecta el crecimiento de las células HEK293.

Products are for research use only. Not for human use. We do not sell to patients.

MS049 Chemical Structure

Cas No.: 1502816-23-0

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
67,00 $
Disponible
5mg
61,00 $
Disponible
10mg
102,00 $
Disponible
25mg
222,00 $
Disponible
50mg
408,00 $
Disponible
100mg
742,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MS 049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC 50 of 34 nM and 43 nM respectively.target: PRMT4, PRMT6;IC 50: 34 nM (PRMT4 ), 43 nM (PRMT6 );In vitro: MS 049 reduces the H3R2me2a mark in HEK293 cells in a concentration dependent manner. MS 049 treatment (72 h exposure) inhibits endogenous PRMT4 methyltransferase activity in a concentration dependent manner resulting in reduced levels of cellular asymmetric arginine dimethylation of Med12 (Med12-Rme2a, IC50 = 1.4 ± 0.1 μM (n = 3)) in HEK293 cells.

[1]. Shen Y et al. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. J Med Chem. 2016 Sep 15.

Reseñas

Review for MS049

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MS049

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.